MedTrace Logo

LiSWT for Nerve Sparing Radical Prostatectomy ED

NCT05877144 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-07-15

No results posted yet for this study

Summary

This phase I clinical trial studies how well low intensity shockwave therapy (LiSWT) improves erectile function in patients who have had nerve-sparing radical prostatectomy (NS-RP), a type of surgery that attempts to save the nerves near the tissues being removed, for prostate cancer. Erectile dysfunction (ED) is a known side effect of the radical prostatectomy procedure. The low intensity shockwave therapy delivers painless electrotherapy pulse to increase blood flow and supply, activation of tissues and wound healing. Using LiSWT after NS-PRP may improve erectile function in men with prostate cancer.

Conditions

  • Erectile Dysfunction
  • Localized Prostate Carcinoma
  • Stage I Prostate Cancer AJCC v8
  • Stage II Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8

Interventions

PROCEDURE

Nerve-Sparing Prostatectomy

Undergo nerve-sparing prostatectomy per standard of care

OTHER

Medical Device Usage and Evaluation

Receive LiSWT

PROCEDURE

Duplex Ultrasound

Undergo DDUS

OTHER

Survey Administration

Ancillary studies

PROCEDURE

Nerve-Sparing Prostatectomy

Undergo nerve-sparing prostatectomy per standard of care

PROCEDURE

Sham Intervention

Receive sham LiSWT

PROCEDURE

Duplex Ultrasound

Undergo DDUS

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

  • Thomas Jefferson University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2025-01-30
Completion
2025-01-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05877144 on ClinicalTrials.gov